Related Experiment Video

Updated: Jun 16, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeted therapies in epithelial ovarian cancer

Nicanor I Barrena Medel1, Jason D Wright, Thomas J Herzog

  • 1Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Journal of Oncology
|January 30, 2010
PubMed

Insights

Epithelial ovarian cancer is deadly, often found late. Targeted therapies show promise for treating this women's cancer by attacking key tumor growth pathways.

Area of Science:

  • Oncology
  • Gynecologic Oncology
  • Cancer Therapeutics

Background:

  • Epithelial ovarian cancer (EOC) presents a significant challenge in women's health due to high mortality rates.
  • Late-stage diagnosis is common, hindering effective treatment and long-term cure.
  • Targeted therapies offer a promising strategy by focusing on critical tumorigenesis and metastasis pathways.

Purpose of the Study:

  • To review promising targeted therapies for epithelial ovarian cancer.
  • To examine treatments exploiting critical pathways in cancer development and spread.
  • To assess the current and future applicability of these targeted agents in EOC.

Main Methods:

  • Literature review of targeted therapeutic strategies.
  • Analysis of pathways involved in epithelial ovarian cancer tumorigenesis and metastasis.
  • Evaluation of the clinical relevance and potential of selected targeted therapies.

Main Results:

  • Identified three key targeted therapies with significant potential for EOC treatment.
  • Highlighted the role of targeting specific molecular pathways in overcoming treatment resistance.
  • Discussed the mechanisms of action and clinical implications of these advanced therapies.

Conclusions:

  • Targeted therapeutics represent a vital advancement in managing epithelial ovarian cancer.
  • Exploiting specific cancer pathways can lead to more effective and personalized treatment strategies.
  • Further research and clinical trials are essential to fully realize the potential of these therapies in improving patient outcomes.

More Related Videos

Transplantation Into the Mouse Ovarian Fat Pad09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...